Access & Equity
Who can reach care, who is excluded by cost or design, and how access models can avoid repeating existing mental-health inequities.
Access is not real if it only works for people who can pay privately, travel to specialist centres, or fit narrow trial-like eligibility rules.
Equity has to be built into the pathway: research representation, referral rules, affordability, geography, cultural trust, safety standards, and respect for Indigenous knowledge and communities all matter.
Use this section to test whether an access model reaches the people it claims to serve, or whether it mainly creates a premium pathway for a small group of patients.
Guides and tools
Comparative access pathways: Oregon, Canada and Australia
A practical comparison of Oregon, Canada, and Australia access pathways, and what they show about legal permission, payment, scale, and equity.
Ensuring Equitable Access
How cost, geography, language, cultural trust, referral rules, and trial representation shape who can receive psychedelic therapy.
Clinical Care vs Retreat Pathways
A scenario resource for Marieke's access choices: clinical care, trials, private specialist care, retreat access, self-directed use, or waiting in standard care.
Further reading
Report on the implementation of the EU anti-racism action plan 2020-2025
analysis source relevant to access & equity.
European Commission | 1 Jan 2023 | EU | Analysis | Reviewed 17 Apr 2026
Healthcare expenditure statistics by function, provider and financing scheme
analysis source relevant to access & equity.
Eurostat | 1 Nov 2024 | EU | Analysis | Reviewed 17 Apr 2026
EFPIA Patients W.A.I.T. Indicator 2023 Survey
analysis source relevant to access & equity.
European Federation of Pharmaceutical Industries and Associations (EFPIA) | 1 Jan 2024 | Europe | Analysis | Reviewed 17 Apr 2026
Notice to stakeholders: Requests to the Special Access Program involving psychedelic-assisted psychotherapy
guidance source relevant to access & equity.
Health Canada | 27 Feb 2023 | Canada | Guidance | Reviewed 17 Apr 2026
Oregon Psilocybin Services
access programme source relevant to access & equity.
Oregon Health Authority | 2 Jan 2023 | US | Access Programme | Reviewed 17 Apr 2026
Ketamine TRD ? Interventional Psychiatry Service
Service-level implementation example for treatment-resistant depression pathway delivery.
Oxford Health NHS Foundation Trust | 1 Jan 2024 | UK | Access Programme | Reviewed 17 Apr 2026